Advanced
Cancer Therapeutics (ACT), a for-profit private company dedicated to
bringing new anti-cancer therapies to market, today announced that it
has signed an agreement to leverage the computational chemistry
expertise of Dr. John Trent, Associate Professor, Department of Medicine
at the University of Louisville’s James
Graham Brown Cancer Center (Brown Cancer Center), to accelerate the
identification of new clinical candidates for the prevention and
treatment of cancer.
“ACT is pleased to be working with Dr. Trent as we collaborate to
accelerate the discovery process to develop potentially lifesaving
therapeutics for cancer patients”
As part of this agreement, over the next twelve months Dr. Trent will
provide contract work for ACT and interface with ACT’s medicinal
chemists to identify the best preclinical candidates for ACT’s top two
small molecule compound programs addressing two novel cancer targets in
the area of cancer metabolism. These programs include
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3) and
Choline Kinase (CK). ACT obtained worldwide exclusive licenses from the
Brown Cancer Center to the PFKFB program in 2008 and for the CK program
in 2009.